PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Last trade$6.40
Day change+$0.25 (+4.07%)
Day range$6.08 – $6.55
Volume701,665
Market cap$130M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PYPD.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PYPD.
Recent news
Company coverage with links to the original publishers.
PolyPid announced results from a pooled microbiology analysis of three randomized trials (N=2,185) showing that D-PLEX₁₀₀ demonstrated lower bacterial burden in breakthrough surgical-site infections (16% vs 27% heavy bacterial growth, p=0.034) and delayed SSI onset compared to standard of care, without selecting for multidrug-resistant organisms. The findings support D-PLEX₁₀₀'s 60% relative risk reduction in SSI prevention demonstrated in the Phase 3 SHIELD II trial.
PolyPid Ltd., a late-stage biopharma company, announced it will report Q4 2025 financial results on February 11, 2026. The company expects to submit its New Drug Application (NDA) for D-PLEX100, its lead product candidate for preventing abdominal colorectal surgical site infections, in early 2026 following positive phase 3 results. A conference call and webcast will be held at 8:30 AM ET on the same day.
PolyPid, a late-stage biopharma company, announced successful results from its Phase 3 SHIELD II trial for its lead product candidate D-PLEX100, which demonstrated a statistically significant reduction in surgical site infections. The company has secured additional funding of $26.7 million through the exercise of warrants, which is expected to extend its runway beyond the anticipated FDA approval of D-PLEX100.
PolyPid, a late-stage biopharma company, announced that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025. The company's lead product candidate, D-PLEX100, is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.
PolyPid, a late-stage biopharma company, will report its Q4 and full-year 2024 financial results and operational highlights on February 12, 2025. The company will host a conference call to discuss the results and provide an update on business operations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.